{
    "nct_id": "NCT03472573",
    "official_title": "A Phase I Trial of Palbociclib in Combination With Dexamethasone in Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukemia (ALL)",
    "inclusion_criteria": "* Patients must have histologic evidence of relapsed or refractory B-cell ALL\n* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less\n* Philadelphia chromosome positive (Ph+) patients must be refractory to or intolerant of standard tyrosine kinase inhibitor therapy\n* Patients must be able to consume oral medication\n* Patients must have recovered to =< grade 1 or stabilized from the toxic effects of any prior chemotherapy (except alopecia)\n* Creatinine clearance (CrCL) >= 60 mL/min/1.73 m^2 calculated by Cockcroft-Gault\n* Total bilirubin < 1.5 x upper limit of normal (ULN)\n* Negative serum or urine pregnancy test for women with child-bearing potential\n* Patients must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan, procedures, and laboratory testing\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients must not have evidence of active central nervous system (CNS) disease\n* Patients must not be receiving any chemotherapy agents (except hydroxyurea); intrathecal methotrexate and intrathecal cytarabine are permissible\n* Patients must not be receiving growth factors (granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF]), except for erythropoietin\n* Patient must not have a concurrent active malignancy for which they are receiving treatment.\n* Patients with other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study are ineligible\n* Patients must not have received any investigational agents within 30 days of study entry unless they have exceeded 5 terminal half-lives of the previous study drug used for treatment\n* Patients must not be pregnant or breastfeeding; pregnancy tests must be obtained for all females of child-bearing potential within 10 days prior to enrollment; males or women of childbearing potential may not participate unless they have agreed to use an effective contraceptive method (defined as hormonal contraceptives, intrauterine devices, surgical contraceptives, or condoms)\n* Patients who have uncontrolled infection are not eligible; patients must have any active infections under control; fungal disease must have been adequately treated for at least 2 weeks before study entry; subjects with bacteremia must have documented negative blood cultures prior to study entry\n* Patients who are candidates for allogeneic transplantation, have a suitable donor, and are willing to undergo transplantation\n* Patients who are eligible for and willing to receive treatment with tisagenlecleucel.",
    "miscellaneous_criteria": ""
}